Five Prime Therapeutics, Inc.
111 Oyster Point Boulevard
San Francisco
California
94080
United States
Website: http://www.fiveprime.com/
About Five Prime Therapeutics, Inc.
Five Prime Therapeutics, Inc. (NASDAQ: FPRX) is a publicly traded, clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics to improve the lives of patients with serious diseases. We have an industry-leading and differentiated drug discovery platform. Our comprehensive proprietary libraries of the extracellular proteome, differentiated screening capabilities and protein therapeutic generation and engineering capabilities comprise a unique and powerful IND engine that positions us to discover novel pathways and targets in immuno-oncology and will continue to generate important development programs. Our success with our drug discovery platform has led to a pipeline that is on track to more than double to five development programs in clinical trials across multiple indications in 2018. We also have several undisclosed research programs at different points of the target validation and molecule generation phases that have the potential to yield our next wave of development-stage therapeutic biologics. And we continue to fuel this process at the earliest stages with new screens planned this year.
Five Prime is committed to innovation and outstanding science to develop effective new drugs for the treatment of severe diseases. We value our culture of openness, collaboration and productivity.
The company is in a strong financial position and has an effective executive team and Board of Directors. Discover more about Five Prime at www.fiveprime.com
Stock Symbol: FPRX
Stock Exchange: Nasdaq
246 articles about Five Prime Therapeutics, Inc.
-
Five Prime Therapeutics, Inc. To Announce Fourth Quarter And Full Year 2014 Financial Results And Host Conference Call On March 17
3/11/2015
-
Five Prime Therapeutics, Inc. To Present At The Barclays Global Healthcare Conference
3/6/2015
-
Five Prime Therapeutics, Inc. To Present At The RBC Capital Markets 2015 Healthcare Conference
2/19/2015
-
Five Prime Therapeutics, Inc. To Present At The 2015 Leerink Global Healthcare Conference
2/5/2015
-
J.P. Morgan: Five Prime Therapeutics, Inc. CEO Says Experimental Drug to Head Into Six New Tumor Trials Via Bristol-Myers Squibb Company
1/16/2015
-
Five Prime Therapeutics, Inc. Announces Closing Of Public Offering
1/12/2015
-
Five Prime Therapeutics, Inc. To Present At The 33rd Annual J.P. Morgan Healthcare Conference
1/9/2015
-
Five Prime Therapeutics, Inc. Prices Public Offering Of Common Stock
1/7/2015
-
Five Prime Therapeutics, Inc. Announces $75 Million Proposed Public Offering Of Common Stock
1/6/2015
-
Five Prime Therapeutics, Inc. To Present At The Oppenheimer 25th Annual Healthcare Conference
12/5/2014
-
Five Prime Therapeutics, Inc. Initiates Patient Dosing In Phase 1 Clinical Trial Evaluating FPA144 In Gastric Cancer
12/5/2014
-
Five Prime Therapeutics, Inc. To Present At The 26th Annual Piper Jaffray Healthcare Conference
11/26/2014
-
Bristol-Myers Squibb Company And Five Prime Therapeutics, Inc. Announce Exclusive Clinical Collaboration To Evaluate The Combination Of Investigational Immunotherapies Opdivo (nivolumab) And FPA008 In Six Tumor Types
11/24/2014
-
Five Prime Therapeutics, Inc. Initiates Dosing Of Rheumatoid Arthritis Patients In Its Phase 1 Clinical Trial Of FPA008
11/17/2014
-
Five Prime Therapeutics, Inc. To Present Data From Healthy Volunteer Cohorts In Phase 1 Trial Of FPA008 At The 2014 American College of Rheumatology/ARHP Annual Scientific Meeting
11/14/2014
-
Five Prime Therapeutics, Inc. Announces Third Quarter 2014 Financial Results
11/11/2014
-
Five Prime Therapeutics, Inc. Announces Presentation At The 2014 Society For Immunotherapy Of Cancer Annual Meeting
11/6/2014
-
Five Prime Therapeutics, Inc. To Announce Third Quarter 2014 Financial Results And Host Conference Call On November 10
11/4/2014
-
Five Prime Therapeutics, Inc. Snags An Expanded Deal Worth $196.3 Million With GlaxoSmithKline
10/24/2014
-
Five Prime Therapeutics, Inc. Appoints Bill Ringo To Its Board Of Directors
10/3/2014